Applied Therapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q1 2018 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Applied Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2018 to Q3 2024.
  • Applied Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$29.7M, a 92% decline year-over-year.
  • Applied Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$92.3M, a 47.6% decline year-over-year.
  • Applied Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$64.5M, a 22.2% increase from 2022.
  • Applied Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$83M, a 21.5% increase from 2021.
  • Applied Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$106M, a 11.8% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$92.3M -$29.7M -$14.2M -92% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 -$78M -$20.4M -$3.26M -19% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-07
Q1 2024 -$74.8M -$21.1M -$10.2M -94.3% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 -$64.5M -$21M -$2.03M -10.7% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-06
Q3 2023 -$62.5M -$15.5M +$3.86M +19.9% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 -$66.4M -$17.2M +$4.35M +20.2% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 -$70.7M -$10.9M +$12.2M +53% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 -$83M -$19M +$8.14M +30% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-06
Q3 2022 -$91.1M -$19.4M +$9.07M +31.9% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$100M -$21.5M +$4.35M +16.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 -$105M -$23.1M +$1.1M +4.54% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 -$106M -$27.1M -$3.36M -14.1% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-23
Q3 2021 -$102M -$28.4M +$1.54M +5.12% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 -$104M -$25.9M +$2.41M +8.5% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-12
Q1 2021 -$106M -$24.2M -$11.7M -94.1% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 -$94.5M -$23.8M -$6.09M -34.4% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-10
Q3 2020 -$88.4M -$30M -$19.2M -179% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 -$69.2M -$28.3M -$19.8M -235% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 -$49.3M -$12.5M -$3.74M -42.8% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-11
Q4 2019 -$45.6M -$17.7M -$11.7M -195% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-18
Q3 2019 -$33.9M -$10.7M -$7.42M -223% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 -$26.5M -$8.44M -$6.1M -261% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-11
Q1 2019 -$20.4M -$8.73M -$6.86M -367% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q4 2018 -$13.5M -$5.99M Oct 1, 2018 Dec 31, 2018 10-K 2020-03-13
Q3 2018 -$3.32M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-13
Q2 2018 -$2.34M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-12
Q1 2018 -$1.87M Jan 1, 2018 Mar 31, 2018 10-Q 2019-06-21
* An asterisk sign (*) next to the value indicates that the value is likely invalid.